Dihexa: Why Retractions Matter
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Dihexa is often discussed as a brain-research compound. Its proposed story centers on HGF and c-Met, a signaling system involved in how cells respond to growth signals. There is an important update: a frequently cited 2014 paper connecting these effects to HGF and c-Met was retracted in 2025. That paper should not be presented as reliable proof that Dihexa builds useful brain connections or improves cognition. Cell and animal claims already require separate testing in people. FDA also notes missing human exposure data for Dihexa acetate. A plausible target is a starting point for research, not a demonstrated memory treatment.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Benoist et al. (2014), now retracted: HGF/c-Met hypothesis
https://pubmed.ncbi.nlm.nih.gov/25187433/
Retracted primary paper, cited only for historical context

[2] Journal retraction notice (2025)
https://pmc.ncbi.nlm.nih.gov/articles/PMC13095468/
Primary publisher retraction notice

[3] FDA peptide safety information: Dihexa acetate
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
US regulator

EVIDENCE LIMITATIONS
The retracted study is not used to substantiate a therapeutic benefit.
Do not equate Dihexa, Dihexa acetate, and other HGF-targeted investigational compounds.
Do not imply a proven cancer risk or proven safety from a signaling hypothesis.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/1151567400532587/